Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...

Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...

Patients with Type 1 diabetes are unable to produce enough insulin naturally. One treatment for Type 1 diabetes is pancreatic islet transplantation, in which groups of cells from a donor pancreas are ...

Researchers have come up with a novel way to prevent fibrosis, which can lead to rejection of implantable medical devices, by incorporating a crystallized immunosuppressant drug into the devices.

New York, NY, August 16, 2012 – JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell ...

Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...

A team of researchers has developed a revolutionary new method for treating type 1 diabetes. Inspired by a spider's web, the team created an easily implantable nanoporous thread that can hold hundreds ...

SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...

LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art ...

JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D ...